

## REFERENCES

1. Moyo TK, Savona MR. Molecular testing in patients with suspected myelodysplastic syndromes. *Curr Hematol Malig Rep* 2016;11(6):441–448.
2. Pang WW, Pluvinage J V., Price EA, et al. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. *Proc Natl Acad Sci U S A* 2013;110(8):3011–3016.
3. Volpe VO, Garcia-Manero G, Komrokji RS. Myelodysplastic syndromes: A new decade. *Clin Lymphoma Myeloma Leuk* 2022;22(1):1–16.
4. Locatelli F, Strahm B. How I treat myelodysplastic syndromes of childhood. *Blood* 2018;131(13):1406–1414.
5. Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: Contemporary review and how we treat. *Am J Hematol* 2016;91(1):76–89.
6. Foster J, Blonquist TM, El-Jawahri A, et al. The end of life for patients with acute myeloid leukemia (AML)- a single center experience. *Blood* 2015;126(23):3318–3318.
7. Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. *Am J Hematol* 2020;95(11):1399–1420.
8. Löwenberg B. Introduction to a review series on myelodysplastic syndromes. *Blood* 2019;133(10):1001–1001.
9. Vink C, Popravko A, Eich C, et al. Proceedings of the 9th international symposium on MDS and SAA in childhood. *Molecular and Cellular Pediatrics* 2021 8:1 2021;8(1):1–24.
10. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. *Leukemia* 2022 36:7 2022;36(7):1703–1719.
11. Galaverna F, Ruggeri A, Locatelli F. Myelodysplastic syndromes in children. *Curr Opin Oncol* 2018;30(6):402–408.
12. Yamazaki H, Nakao S. Border between aplastic anemia and myelodysplastic syndrome. *Int J Hematol* 2013;97(5):558–563.
13. Estey E, Hasserjian RP, Döhner H. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. *Blood* 2022;139(3):323–332.
14. Rau ATK, Shreedhara AK, Kumar S. Myelodysplastic syndromes in children: Where are we today? *Ochsner J* 2012;12(3):216.
15. Agustin BN, Maani H, Desywar D. Gambaran Hematologi Pasien Myelodysplastic Syndrome di RSUP Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas* 2019;8(3):500.

16. Hasegawa D, Chen X, Hirabayashi S, et al. Clinical characteristics and treatment outcome in 65 cases with refractory cytopenia of childhood defined according to the WHO 2008 classification. *Br J Haematol* 2014;166(5):758–766.
17. Yang W, Liu C, Li X, et al. Analysis of Clinical Characteristics of Childhood Myelodysplastic Syndrome with Increased Blasts (cMDS-IB). *Blood* 2022;140:11475–11476.
18. Hasegawa D. The current perspective of low-grade myelodysplastic syndrome in children. *Int J Hematol* 2016;103(4):360–364.
19. Kardos G, Baumann I, Passmore SJ, et al. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. *Blood* 2003;102(6):1997–2003.
20. Olcay L, Yetgin S. Disorders Mimicking Myelodysplastic Syndrome and Difficulties in its Diagnosis. In: *Myelodysplastic Syndromes*. InTech, 2016;
21. Niemeyer CM, Baumann I. Classification of Childhood Aplastic Anemia and Myelodysplastic Syndrome.
22. AlMozain N, Mashi A, Alneami Q, et al. Spectrum of myelodysplastic syndrome in patients evaluated for cytopenia(s). A Report from a Reference Centre in Saudi Arabia. *Hematol Oncol Stem Cell Ther* 2020;
23. Iwafuchi H. The histopathology of bone marrow failure in children. *J Clin Exp Hematop* 2018;58(2):68.
24. Hong M, He G. The 2016 revision to the World Health Organization classification of myelodysplastic syndromes. *J Transl Int Med* 2017;5(3):139–143.
25. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for Myelodysplastic Syndromes. *Blood* 2012;120(12):2454.